SOMALOGIC INC (SLGC)

US83444K1051 - Common Stock

2.1  -0.1 (-4.55%)

After market: 2 -0.1 (-4.76%)

Fundamental Rating

3

SLGC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. SLGC has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, SLGC is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year SLGC has reported negative net income.
SLGC had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -23.08%, SLGC is not doing good in the industry: 68.85% of the companies in the same industry are doing better.
SLGC has a Return On Equity of -26.25%. This is comparable to the rest of the industry: SLGC outperforms 40.98% of its industry peers.
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROIC N/A
ROA(3y)-17.05%
ROA(5y)N/A
ROE(3y)-20.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SLGC's Gross Margin of 41.14% is in line compared to the rest of the industry. SLGC outperforms 44.26% of its industry peers.
SLGC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for SLGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.12%
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

SLGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLGC has been increased compared to 1 year ago.
There is no outstanding debt for SLGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.03 indicates that SLGC is not a great score, but indicates only limited risk for bankruptcy at the moment.
SLGC has a Altman-Z score (2.03) which is in line with its industry peers.
There is no outstanding debt for SLGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.03
ROIC/WACCN/A
WACC12.33%

2.3 Liquidity

A Current Ratio of 17.77 indicates that SLGC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.77, SLGC belongs to the top of the industry, outperforming 95.08% of the companies in the same industry.
A Quick Ratio of 17.27 indicates that SLGC has no problem at all paying its short term obligations.
SLGC has a Quick ratio of 17.27. This is amongst the best in the industry. SLGC outperforms 95.08% of its industry peers.
Industry RankSector Rank
Current Ratio 17.77
Quick Ratio 17.27

4

3. Growth

3.1 Past

SLGC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
Looking at the last year, SLGC shows a very negative growth in Revenue. The Revenue has decreased by -19.73% in the last year.
SLGC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.77% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q33.33%
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5YN/A
Revenue growth Q2Q-47.13%

3.2 Future

SLGC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.80% yearly.
SLGC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.84% yearly.
EPS Next Y-2.43%
EPS Next 2Y3.89%
EPS Next 3Y4.51%
EPS Next 5Y3.8%
Revenue Next Year-12.14%
Revenue Next 2Y1.69%
Revenue Next 3Y7.5%
Revenue Next 5Y11.84%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLGC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y4.51%

0

5. Dividend

5.1 Amount

No dividends for SLGC!.
Industry RankSector Rank
Dividend Yield N/A

SOMALOGIC INC

NASDAQ:SLGC (1/5/2024, 7:26:28 PM)

After market: 2 -0.1 (-4.76%)

2.1

-0.1 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap396.23M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 41.14%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 17.77
Quick Ratio 17.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-2.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y